Childhood cancer research receives roughly $78 million in dedicated federal funding through two main programs, out of a total National Cancer Institute budget of $7.2 billion. That works out to just over 1% of the NCI’s budget in earmarked pediatric dollars, though the actual figure is higher when you count broader research grants that include pediatric components. The number you’ve probably seen floating around the internet is 4%, and while its exact origin is hard to pin down, the core message holds: pediatric cancer research gets a small fraction of federal cancer spending.
Where Federal Funding Stands
The two largest dedicated streams of federal money for childhood cancer research flow through the NCI. The Childhood Cancer Data Initiative (CCDI) was launched in 2020 with $50 million per year, proposed for a 10-year run. The Childhood Cancer STAR Act, signed into law in 2018, adds $28 million annually. That money supports biorepositories that collect biological samples and clinical data from children enrolled in cancer trials, along with research into long-term survivorship for kids who beat cancer.
In 2024, the Department of Health and Human Services announced it would double the CCDI’s budget from $50 million to $100 million, with a focus on using artificial intelligence to improve data analysis. That increase brings the combined dedicated pediatric total closer to $128 million, a meaningful jump but still a small share of the NCI’s $7.2 billion in available funds.
Why the Number Feels So Low
Cancer in children is rare. About 15,000 children and adolescents are diagnosed in the U.S. each year, compared to roughly 1.9 million cancer diagnoses across all ages. Funding decisions at the federal level are influenced by disease burden across the whole population, which naturally tilts resources toward cancers that affect far more people, like breast, lung, and colorectal cancer.
But rarity cuts both ways. Because fewer children get cancer, there are fewer patients available for clinical trials, which makes drug development slower and more expensive per patient. That same dynamic discourages private investment. Only 16% of cancer clinical trials that include children are sponsored by the pharmaceutical industry, compared to 33% of adult cancer trials. Even within pediatric medicine more broadly, industry sponsors 30% of trials for other childhood diseases. Childhood cancer sits at the bottom of the list for private R&D dollars, which means the gap left by limited federal funding isn’t being filled by drugmakers either.
The Full Picture Is Harder to Calculate
The $78 million (or $128 million with the CCDI increase) represents only the funding that’s explicitly earmarked for pediatric cancer. It doesn’t capture the full scope of federal spending that benefits children with cancer. Some NCI grants fund basic biology research on tumor types that affect both adults and children. Discoveries in immunotherapy, genomics, and drug delivery often cross age boundaries. The NCI doesn’t neatly separate every dollar by age group, which is part of why the exact percentage is so hard to nail down and why different advocacy groups cite slightly different numbers.
Still, the dedicated pediatric funding is what researchers can count on for studies focused specifically on childhood cancers, many of which are biologically distinct from adult cancers and require their own treatment approaches. A child with leukemia isn’t getting a smaller version of an adult’s disease. The tumor biology, the treatment protocols, and the long-term side effects are fundamentally different, which is why advocates push for funding that’s specifically directed at pediatric research rather than hoping for spillover benefits from adult cancer studies.
What the STAR Act Changed
Before the STAR Act passed in 2018, there was no single federal law dedicated to childhood cancer research infrastructure. The act authorized the NCI to expand its collection of tumor samples and clinical data from pediatric patients in clinical trials, creating a centralized resource that researchers across the country can access. It also directed funding toward survivorship research, recognizing that children who survive cancer often face decades of health consequences from their treatment, including heart damage, secondary cancers, and cognitive effects.
The STAR Act was a bipartisan effort and one of the most significant legislative steps specifically for childhood cancer. Its $28 million annual appropriation is modest by federal standards, but it created a permanent infrastructure that didn’t exist before.
How Nonprofit Funding Fills the Gap
Because federal and industry funding is limited, nonprofit organizations play an outsized role in childhood cancer research. Groups like Alex’s Lemonade Stand Foundation, St. Baldrick’s Foundation, and CureSearch collectively fund tens of millions of dollars in grants each year. St. Baldrick’s alone has funded over $326 million in research since its founding. These organizations often fund early-stage research or high-risk projects that federal agencies are less likely to support, serving as a bridge between an idea and the point where it can attract larger government grants.
For families looking to support childhood cancer research directly, these nonprofits are where donations have the most targeted impact. Federal funding is shaped by congressional budgets and political priorities. Nonprofit dollars go straight to researchers working on pediatric-specific questions.